ArticleAnnals of the rheumatic diseases2021

Investigating changes in disease activity as a mediator of cardiovascular risk reduction with methotrexate use in rheumatoid arthritis.

Tate M Johnson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.